Medical marijuana declined as PTSD treatment in Colorado

Medical marijuana declined as PTSD treatment in Colorado

A piece of bad news for sufferers of the post traumatic stress disorder in Colorado, as they will not be allowed to legally qualify for medical marijuana prescription any time soon. The state’s officials have voted against cannabis treatment for PTSD, despite the petition being signed by over 6,000 PTSD patients. Considered one of the most ‘pot-friendly’ states, Colorado allows medical marijuana to be prescribed in a variety of conditions, most notably, cancer, AIDS, severe pain and nausea. It has been almost 15 years since a new condition was added to the list.

The Wednesday vote was the third time the Colorado Medical Board rejected the petition. A number of PTSD patients were present at the hearing, along with their lawyers, and ended up displeased with the outcome. As a reason for their rejection, the Board Committee stated that ‘currently the data is lacking to firmly prove the effectiveness of this type of treatment’.

Despite this prohibition, statistics show that PTSD sufferers are using cannabis anyway, as recreation smokers. In Colorado, you don’t need a prescription to buy and possess up to one ounce of marijuana. But the problem is that recreational marijuana is taxed 19%, while it’s only 2% for medical cannabis. Also, with prescription you are allowed to possess 2 ounces instead of just one. Last but not least, people under 21 cannot legally use recreational marijuana. And out of about 113,000 registered medical marijuana patients in the state, more than 6,000 are minors.

Colorado’s Chief Health Officer, Larry Wolk, who is a supporter of petition, but has no vote on the Board, commented on the ruling: ‘These people need medical counseling, but keep self-medicating with recreational cannabis, rather than turning to professionals for guidance’. On the other hand, Wolk confirms that medical research data is insufficient for cannabis treatment of PTSD. ‘We will be providing a $3.4 million budget for the series of clinical studies next year, that would hopefully give us a more clear understanding of the matter.’ After that, Wolk is convinced that the Board decision might be reconsidered.

Latest Posts From This Category

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Latest Posts